Companies › Sinovac Biotech
7 active drug programs in 12 registered trials: 7 Phase 3, 4 Phase 4, 1 Phase 1; Infectious disease, Vaccines; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Healive (hepatitis A vaccine (human diploid cell), inactivated) Inactivated hepatitis A virus vaccine | – | Phase 4 | Hepatitis A; Hepatitis A Vaccine | Sep 2027 |
| sIPV (Sabin Strain Inactivated Poliovirus Vaccine) Inactivated poliovirus vaccine using Sabin strain | – | Phase 4 | Poliomyelitis | – |
| wIPV (Wild Strain Inactivated Poliovirus Vaccine) Inactivated poliovirus vaccine using wild strain | – | Phase 4 | Poliomyelitis | – |
| Group ACYW135 Meningococcal Conjugate Vaccine Meningococcal polysaccharide conjugate vaccine targeting serogroups A, C, Y, W135 | – | Phase 3 | Epidemic Meningitis | Nov 2026 |
| bivalent enterovirus vaccine (Vero cell), inactivated inactivated bivalent enterovirus vaccine targeting Enterovirus 71 and Coxsackievirus A16 | EV71, CA16 | Phase 3 | Hand, Foot, and Mouth Disease(HFMD) | Nov 2026 |
| Sinovac QIV Influenza vaccine (split virion), inactivated, quadrivalent | – | Phase 3 | Influenza | – |
| Lyophilized herpes zoster virus mRNA vaccine mRNA vaccine encoding herpes zoster virus antigens | – | Phase 1 | Herpes Zoster | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07354269 | sIPV (Sabin Strain Inactivated Poliovirus Vaccine) | Phase 4 | Poliomyelitis | Infectious disease | Apr 2026 |
| NCT07211152 | Sinovac QIV | Phase 3 | Influenza | Infectious disease | Jun 2026 |
| NCT07457060 | sIPV (Sabin Strain Inactivated Poliovirus Vaccine) | Phase 4 | Poliomyelitis | Infectious disease | Sep 2026 |
| NCT07457060 | wIPV (Wild Strain Inactivated Poliovirus Vaccine) | Phase 4 | Poliomyelitis | Infectious disease | Sep 2026 |
| NCT07505888 | Group ACYW135 Meningococcal Conjugate Vaccine | Phase 3 | Epidemic Meningitis | Vaccines | Nov 2026 |
| NCT06734832 | bivalent enterovirus vaccine (Vero cell), inactivated | Phase 3 | Hand, Foot, and Mouth Disease(HFMD) | Infectious disease | Nov 2026 |
| NCT07505836 | Group ACYW135 Meningococcal Conjugate Vaccine | Phase 3 | Epidemic Meningitis | Vaccines | Jan 2027 |
| NCT07505810 | Group ACYW135 Meningococcal Conjugate Vaccine | Phase 3 | Epidemic Meningitis | Vaccines | Apr 2027 |
| NCT07505823 | Group ACYW135 Meningococcal Conjugate Vaccine | Phase 3 | Epidemic Meningitis | Vaccines | Apr 2027 |
| NCT07400003 | Lyophilized herpes zoster virus mRNA vaccine | Phase 1 | Herpes Zoster | Vaccines | Apr 2027 |
| NCT07793227 | Healive (hepatitis A vaccine (human diploid cell), inactivated) | Phase 3 | Hepatitis A Vaccine | Vaccines | Sep 2027 |
| NCT06058416 | Healive (hepatitis A vaccine (human diploid cell), inactivated) | Phase 4 | Hepatitis A | Infectious disease | Mar 2028 |
Cash and short-term investments of $6.0bn on 2025-12-31; operating cash outflow about $514m a year; runway about 140 months at that burn, to Aug 2037; 6 of 6 coming phase 2-3 readouts fall inside that runway
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Liaoning Chengda Biotechnology MAXVAX Biotechnology Limited Liability Company CanSino Biologics Xiamen Innovax Biotech Anhui Zhifei Longcom Biologic Pharmacy
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.